Navigation Links
NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Date:3/24/2008

IRVINE, Calif., March 24 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals, Inc. (OTC Bulletin Board: NURX) today announced it has dosed the first patient in a Phase I clinical trial of the first-in-class rexinoid receptor (RXR) agonist NRX4204.

The single-center study, which NuRx expects to complete in the fourth quarter of this year, is designed to evaluate the safety and tolerability of the compound. NRX4204 is the company's first drug candidate in clinical trials.

"Our preclinical data show that NRX4204 is a highly potent and specific, orally bio-available RXR agonist that is effective in models of non-small cell lung cancer and breast cancer," said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend to pursue the development of this compound as a treatment for both indications. There are no rexinoid treatments currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, first-in-class rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. Th
'/>"/>

SOURCE NuRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SAINT PAUL, Minn. , May 23, 2013 /PRNewswire/ ... Angeion Corporation), a global medical technology company, today scheduled ... the second quarter of fiscal year 2013, ended April ... ET on Thursday, May 30, 2013. The Company will ... year 2013 after the markets close on Thursday, May ...
(Date:5/23/2013)... , May 23, 2013  Hadasit Bio-Holdings Ltd. ... of biotech companies, based on intellectual property developed ... Israel ,s foremost medical research center, today ... Ltd., received significant funding from the Israeli Ministry ... Scientist (OCS) to support product development and advance ...
(Date:5/23/2013)... SANTA MONICA, Calif. , May 23, 2013 /PRNewswire-USNewswire/ ... of a program that would have required them to ... announced today by Consumer Watchdog and Whatley Kallas LLC.  ... San Diego Superior Court, alleged that Blue Cross,s mandatory ... HIV/AIDS patients, threatening their health and privacy. ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
... March 16 SpineMark CRO Management, a wholly-owned ... recently signed an agreement with Ranier Technology, a ... provide contract research support services for the Ranier CAdisc™-L ... device for treatment of degenerative disc disease in the ...
... ) today announced that the company will hold its annual meeting of stockholders on Wednesday, June 9, 2010 at 9:00a.m. Pacific Time ... . , ... , , ... ...
Cached Medicine Technology:San Diego Based CRO Signs Agreement With UK Based Spinal Device Manufacturer 2San Diego Based CRO Signs Agreement With UK Based Spinal Device Manufacturer 3PDL BioPharma To Hold Annual Meeting of Stockholders on June 9, 2010 2
(Date:5/25/2013)... 25, 2013 The Slim Weight Patch has ... results. This is due to the highly sought after ingredients ... weight patch offers an extra 2 months supply & premium ... and get the body you desire faster than ever. , ... , With Slim weight patch consumers can observe instant ...
(Date:5/25/2013)... 2013 For college students, few ... Increasingly, they are turning to prescription stimulants like ... For more on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm ... warns that students who pick up Adderall, “just ... for developing a physical and psychological dependency. While ...
(Date:5/25/2013)... 25, 2013 Superior Magnetics for Pain ... in seconds for arthritis, tendinitis and bursitis , Pain ... relief products announced a magnetic bracelet so ... for pain relief is demonstrated at fairs and festivals. ... Gauss magnets and has customers often report pain relief ...
(Date:5/25/2013)... 25, 2013 http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html , ... judge's overturning of a jury's award of $6.5 million ... trial* in the country over allegations that the diabetes ... files. , The judge in the case ruled that ... his cancer was caused by the medication.** , Bloomberg ...
(Date:5/24/2013)... FL (PRWEB) May 25, 2013 The ... Cellulite Whisperer ® products from Sublime Beauty®. The ... to diminish cellulite, and many of the ingredients are ... deal with and is dreaded by many women," says ... concentrated holistic plan, women can diminish their cellulite." The ...
Breaking Medicine News(10 mins):Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Magnetic bracelet relieves pain in seconds announces Superior Magnetics 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 3Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 4Health News:"Get Ready for Summer Sale" at Sublime Beauty® Continues: New Cellulite Whisperer® Products 2
... Aug. 19 (HealthDay News) -- At 3 years of age, Pablo ... He also had frequent severe constipation, so much so that he ... of Alexandria, Va. Because of the prolapse, a condition in ... doctors worried that the boy, who is now 13, had cystic ...
... delicti is a plain flacon from among the possessions of ... exhibit in the permanent collection of the Egyptian Museum of ... the vessel may have held a deadly secret. This is ... Helmut Wiedenfeld from the university,s Pharmacology Institute just discovered. After ...
... (August 19, 2011) Antibiotics can help ward off serious ... catheters for their dialysis treatments. But if antibiotics are used ... to the drugs. A new randomized controlled clinical trial ... used to treat other serious infections may be a safe ...
... News) -- Cases of Legionnaire,s disease in the United States ... report shows. And while Legionnaires, disease is serious and ... for concern, most people recover with antibiotic treatment, officials said. ... Centers for Disease Control and Prevention rose from 1,110 in ...
... 18 (HealthDay News) -- Two gene variations that increase smokers, ... Smokers with the variants also tend to smoke more and ... Researchers at the Centre for Addiction and Mental Health in ... cancer and 443 current or former smokers without cancer. ...
... Society congratulates Dietrich Manzey, Maria Luz, Stefan Mueller, ... receiving the 2011 Human Factors Prize for their ... Assistance on Performance, Waorkload, Situation Awareness, and Acquisition ... is health-care ergonomics, broadly defined to include research ...
Cached Medicine News:Health News:Gluten-Free Set This Boy Free 2Health News:Deadly medication? 2Health News:Deadly medication? 3Health News:Acne-treating antibiotic cuts catheter infections in dialysis patients 2Health News:Cases of Legionnaire's Disease Tripled in 10 Years 2Health News:Gene Variants That Boost Lung Cancer Risk Identified 2Health News:Paper on automation in surgery wins 2011 Human Factors Prize for Excellence in HF/E Research 2Health News:Paper on automation in surgery wins 2011 Human Factors Prize for Excellence in HF/E Research 3Health News:Paper on automation in surgery wins 2011 Human Factors Prize for Excellence in HF/E Research 4
A One Piece Support Garment - any length or size...
Body Suit w/Bra torso, Front Closure...
Gynecomastia Vest...
Ideal for breast compression and contouring breast cups....
Medicine Products: